Journals / The European Research Journal / 2022 / Cilt: 8 - Sayı: 1

Effects of microRNAs in hypertension disease

Pages
131–138
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Finally, with gene targeting studies, we think that miRNAs, which can be biomarkers and molecular agents, will hold promise in preventing the progression of hypertension in the future, and we hope that they can create ideas for future studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Hypertension is a cardiovascular disease which is a very common hemodynamic syndrome, and it has different prevalence in different regions as it is common all over the world.
📊
Key Findings & Data:In recent studies, it is known that microRNAs (miRNAs) play an important role in hypertension disease and that miRNA expressions are regulated by epigenetic mechanisms.
💡
Conclusion & Impact:Finally, with gene targeting studies, we think that miRNAs, which can be biomarkers and molecular agents, will hold promise in preventing the progression of hypertension in the future, and we hope that they can create ideas for future studies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Hypertension is a cardiovascular disease which is a very common hemodynamic syndrome, and it has different prevalence in different regions as it is common all over the world. In recent studies, it is known that microRNAs (miRNAs) play an important role in hypertension disease and that miRNA expressions are regulated by epigenetic mechanisms. There are also studies proving that microRNAs are new therapeutic targets for pulmonary arterial hypertension, and miRNAs can participate in the pathophysiology of hypertension in many ways and it can be used as a biomarker for hypertension disease. It is thought that miRNAs can be effective in the diagnosis and treatment of hypertension and further studies are needed. Recently, the relationship between miRNAs and hypoxia has also been focused on and has been taken into account in studies. In this review, we aimed to present the effects of miRNAs on hypertensive disease and current approaches. Finally, with gene targeting studies, we think that miRNAs, which can be biomarkers and molecular agents, will hold promise in preventing the progression of hypertension in the future, and we hope that they can create ideas for future studies.

🔖

Cite This Article

ALTINTAŞ, N., TONK, O., YILMAZ, Ö. S. (2022). Effects of microRNAs in hypertension disease. The European Research Journal, Cilt: 8 - Sayı: 1, 131–138. https://ajindex.com/articles/597373

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Wang Y, Jin L. miRNA-145 is associated with spontaneous hypertension by targeting SLC7A1. Exp Ther Med 2018;15:548- 52
  2. Li X, Wei Y, Wang Z. microRNA-21 and hypertension. Hypertens Res 2018;41:649-61
  3. Wise IA, Charchar FJ. Epigenetic modifications in essential hypertension. Int J Mol Sci 2016;17:451
  4. Jalnapurkar S, Mangaonkar A, Mondal A, Burke J, Fulzele S, Kolhe R. MicroRNAs: as a novel potential tool for diagnosis, prognosis, and therapeutic agents in hypertension. Hypertens Cardiol 2015;1:14-22
  5. Liu H, Yin T, Yan W, Si R, Wang B, Chen M, et al. Dysregulation of microRNA-214 and PTEN contributes to the pathogenesis of hypoxic pulmonary hypertension. Int J Chron Obstruct Pulmon Dis 2017;12:1781-91
  6. Güzelgül F, Aksoy K. A gene expression regulator: miRNA. Arşiv Kaynak Tarama Dergisi 2015;24:472-93
  7. Zhou G, Chen T, Raj JU. MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2015;52:139-51
  8. Shomron N, Levy C. MicroRNA-biogenesis and pre-mRNA splicing crosstalk. J Biomed Biotechnol 2009;2009:594678
  9. Gibbons A, Udawela M, Dean B. Non-coding RNA as novel players in the pathophysiology of schizophrenia. Noncoding RNA 2018;4:11
  10. Beitzinger M, Meister G. Experimental identification of microRNA targets by immunoprecipitation of argonaute protein complexes. In: Dalmay T (eds). MicroRNAs in Development. Methods in Molecular Biology (Methods and Protocols). Humana Press. 2011
  11. Frydrych Capelari É, da Fonseca GC, Guzman F, Margis R. Circular and micro RNAs from arabidopsis thaliana flowers are simultaneously isolated from AGO-IP libraries. Plants (Basel) 2019;8:302
  12. Arif M, Sadayappan S, Becker RC, Martin LJ, Urbina EM. Epigenetic modification: a regulatory mechanism in essential hypertension. Hypertens Res 2019;42:1099-113
  13. Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol 2019;51:11-7
  14. Cheng X, Wang Y, Du L. Epigenetic modulation in the initiation and progression of pulmonary hypertension. Hypertension 2019;74:733-9
  15. Napoli C, Benincasa G, Loscalzo J. Epigenetic inheritance underlying pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2019;39:653-64
  16. Erkoç, Sultan Balız. Eskişehir Mahmudiye’de erişkinlerde hipertansiyon insidansı ve risk faktörleri. Halk Sağlığı Anabilim Dalı, Tıpta Uzmanlık Tezi, Eskişehir, 2013
  17. Watanabe K, Narumi T, Watanabe T, Otaki Y, Takahashi T, Aono T, et al. The association between microRNA-21 and hypertension